Skip to main content
. 2023 Jan 12;15(2):489. doi: 10.3390/cancers15020489

Figure 3.

Figure 3

B induces caspase dependent apoptosis in Caco2 cells. (a) Nuclei condensation of Caco2 cells upon treatment with B (20, 60 µg/mL) or EL000327 (60 µg/mL) for 12 h, as determined by Hoechst staining. Arrowheads indicate nuclear condensation in cells. (b) Quantification of condensed nuclei in Caco2 cells treated with indicated concentrations of B or EL000327. (c) Caspase 3/7 (green) staining of Caco2 cells treated with B (20, 60 µg/mL) or EL000327 (60 µg/mL) for 48 h. (d) Quantification of apoptotic cells stained with Caspase 3/7 after treatment with the indicated concentrations of B or EL000327. (e) Annexin V staining of Caco2 cells treated with B (20, 60 µg/mL) or EL000327 (60 µg/mL) for 48 h in the presence or absence of the caspase inhibitor Z-VAD-FMK (10 µM). (f) Quantification of apoptotic cells stained with Annexin V after treatment with the indicated concentrations of B or EL000327 in the presence or absence of Z-VAD-FMK (10 µM). (g) Flow cytometric analysis of dead cells stained by Annexin v-FITC (apoptotic cells) and PI (necrotic cells) upon the treatment of B (20, 60 µg/mL) or EL000327 (60 µg/mL) for 48 h in the presence or absence of Z-VAD-FMK (10 µM). (h) Quantification of the percentage of apoptotic cells treated with indicated concentrations of B and EL000327 and analyzed by flow cytometry in the presence or absence of Z-VAD-FMK (10 µM). Results are representative of three independent experiments. Data represent the mean ± S.D. ** p < 0.01, *** p < 0.001; compared with the DMSO-treated control or Z-VAD-FMK treated group.